Last reviewed · How we verify
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
Details
| Lead sponsor | The Cooper Health System |
|---|---|
| Phase | PHASE4 |
| Status | UNKNOWN |
| Enrolment | 132 |
| Start date | Wed Jul 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Clostridium Difficile Infection Recurrence
Interventions
- Bezlotoxumab Injection